Chandresh Harjivan

With more than 25 years of experience spanning public health, government, and the biopharmaceutical industry, Chandresh Harjivan has worked with the leadership of nearly every major pharmaceutical company, U.S. health agency, and global health organization to accelerate the development and delivery of lifesaving vaccines, therapeutics, and diagnostics. His last full-time position was as a special assistant to the president in the White House, where he reported directly to the President overseeing vaccines, therapeutics, diagnostics, research and development, and supply chain and response plans to strengthen the nation’s readiness for biological threats. In 2021 he cofounded SaponiQx, a next-generation vaccine adjuvant company valued at $250 million on exit. Its key product, STIMULON™ QS-21, is a crucial component in vaccines such as GSK’s Shingrix. He was a key architect of Operation Warp Speed, the historic federal initiative that developed and distributed the Covid-19 vaccine, sitting side by side with the CEO and COO from its inception to close. It saved $1 trillion and 3 million lives. Chan was a aanaging director and partner at Boston Consulting Group, where he founded and led the Public Sector Health Practice, and prior to that was a Senior Partner at PwC, where he founded and led the Global Health Practice.